# Whole Genome Analysis - Variantyx

**Date**: 2024-12-14
**Sample Collection Date**: 2024-09-07
**Provider**: Rogério Rogério Rita
**Genetic Counselors**: Rogerio R Rita and Richard Boles
**Lab**: Variantyx (CLIA #22D2140582)
**Patient**: Isaac França
**DOB**: June 6, 2018
**Test ID**: 202806864 / 84820
**Report ID**: 613eaa48f300

---

## Test Information

| Parameter | Value |
|-----------|-------|
| Cohort | Trio |
| Sample Type | Saliva |
| Sample Collection Date | Sep 7, 2024 |
| Sample Received Date | Sep 11, 2024 |
| Processed Date | Sep 18, 2024 |
| Indication for Testing | Autism, Delayed speech and language development |

## Included Analyses

- Small Sequence Variants
- Mitochondrial Genome
- Structural Variants
- Short Tandem Repeats

## Optional Findings

- ACMG Secondary Findings: **Opted in**
- Actionable Findings: **Opted in**

---

## Results: NEGATIVE

### Summary of Findings

No pathogenic or likely pathogenic variants sufficient to cause disease were identified that have been associated with the clinical symptoms provided.

### Primary Findings

No findings were identified.

### ACMG Secondary Findings

No variants were identified in the American College of Medical Genetics and Genomics (ACMG) list of genes to be reported as secondary findings.

### Actionable Findings

No other actionable findings were identified at the time of reporting.

### Carrier Findings

No carrier findings were identified at the time of reporting.

### Other Variants Findings

No other findings were identified at the time of reporting.

### Supplementary Findings

No supplementary findings were identified at the time of reporting.

---

## Sample Information

| Patient | Sex | Date of Birth | Specimen Type | Date Collected | Date Received |
|---------|-----|---------------|---------------|----------------|---------------|
| Proband (Isaac França) - 202806864 | M | Jun 6, 2018 | Saliva | Sep 7, 2024 | Sep 11, 2024 |
| Father - 202666150 | M | - | Saliva | Sep 7, 2024 | Sep 11, 2024 |
| Mother - 202666293 | F | - | Saliva | Sep 7, 2024 | Sep 11, 2024 |

---

## Follow Up Recommendations

Genetic counseling is recommended to review both positive and negative results, as well as secondary and incidental findings, if identified. Test results may benefit from periodic reevaluation for new clinical associations to variants and updated variant classification.

---

## Pharmacogenomics Results

### Patient Genotype Summary

| Gene | Genotype | Metabolizer Status |
|------|----------|--------------------|
| CYP2B6 | *1/*1 | Normal Metabolizer |
| CYP2C19 | *1/*17 | Rapid Metabolizer |
| CYP2C9 | *1/*1 | Normal Metabolizer |
| CYP2D6 | *1/*4 | Intermediate Metabolizer |
| CYP3A5 | *3/*3 | Poor Metabolizer |
| CYP4F2 | *1/*1 | Indeterminate |
| DPYD | c.85T>C (*9A)/c.1896T>C | Normal Metabolizer |
| NAT2 | *4/*5 | Indeterminate |
| NUDT15 | *1/*1 | Normal Metabolizer |
| SLCO1B1 | *1/*14 | Normal Function |
| TPMT | *1/*1 | Normal Metabolizer |
| UGT1A1 | *1/*36 | Normal Metabolizer |
| VKORC1 | Reference/Reference | Indeterminate |

### Clinically Significant Pharmacogenomic Findings

#### CYP2D6 Intermediate Metabolizer (*1/*4)

Drugs with potential impact on pharmacokinetic properties (may alter systemic concentrations):

**Antidepressants:**
- Amitriptyline (Elevil)
- Clomipramine (Anafranil)
- Desipramine (Norpramin)
- Doxepin (Sinequan)
- Imipramine (Tofranil)
- Nortriptyline (Pamelor)
- Paroxetine
- Amoxapine
- Trimipramine

**Oncology:**
- Tamoxifen - Results in lower systemic active metabolite concentrations

**Neurology:**
- Meclizine - Data Support Therapeutic Management Recommendations. May affect systemic concentrations. Monitor for adverse reactions and clinical effect.

**Pediatrics (Rare Congenital Diseases):**
- Eliglustat - Data Support Therapeutic Management Recommendations. Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Dosages based on CYP2D6 metabolizer status.

#### CYP2C19 Rapid Metabolizer (*1/*17)

Affected drugs (no specific recommendations available):
- Citalopram (Celexa)
- Escitalopram (Lexapro)
- Doxepin (Sinequan)
- Brivaracetam
- Clobazam
- Voriconazole
- Carisoprodol
- Diazepam
- Pantoprazole, Dexlansoprazole, Esomeprazole, Omeprazole, Rabeprazole (PPIs)
- Flibanserin
- Clopidogrel

#### CYP3A5 Poor Metabolizer (*3/*3)

- Tacrolimus - No available recommendation

#### NAT2 Indeterminate (*4/*5)

- Amifampridine - Indeterminate metabolic status. Follow up with additional risk assessment.
- Amifampridine Phosphate - Indeterminate metabolic status. Follow up with additional risk assessment.

### Full Drug-Gene Interaction Tables

#### Psychology/Psychiatry (Antidepressants, Anti-psychotics)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Amphetamine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Aripiprazole | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Aripiprazole Lauroxil | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Atomoxetine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Brexpiprazole | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Clozapine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Iloperidone | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Pimozide | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Thioridazine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Venlafaxine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Vortioxetine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Perphenazine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Fluvoxamine (Luvox) | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Protriptyline | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Risperidone | CYP2D6 (*1/*4) | Intermediate | No recommendation |

#### Neurology (AEDs, antiemetics, dementia medications)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Deutetrabenazine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Tetrabenazine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Valbenazine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Donepezil | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Galantamine | CYP2D6 (*1/*4) | Intermediate | No recommendation |

#### Anesthesiology (Pain Medications, muscle relaxants, paralytics)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Codeine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Lofexidine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Tramadol | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Dronabinol | CYP2C9 (*1/*1) | Normal | No recommendation |

#### Cardiology

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Propafenone | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Carvedilol | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Metoprolol | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Nebivolol | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Propranolol | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Simvastatin | SLCO1B1 (*1/*14) | Normal Function | No recommendation |
| Rosuvastatin | SLCO1B1 (*1/*14) | Normal Function | No recommendation |

#### Hematology (Anticoagulants)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Clopidogrel | CYP2C19 (*1/*17) | Rapid | No recommendation |
| Warfarin | CYP2C9 (*1/*1) | Normal | No recommendation |
| Warfarin | CYP4F2 (*1/*1) | Indeterminate | No recommendation |
| Warfarin | VKORC1 (Ref/Ref) | Indeterminate | No recommendation |
| Avatrombopag | CYP2C9 (*1/*1) | Normal | No recommendation |

#### Oncology (Targeted therapies, chemotherapy)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Capecitabine | DPYD | Normal | No recommendation |
| Fluorouracil | DPYD | Normal | No recommendation |
| Gefitinib | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Irinotecan | UGT1A1 (*1/*36) | Normal | No recommendation |
| Mercaptopurine | TPMT (*1/*1), NUDT15 (*1/*1) | Normal | No recommendation |
| Thioguanine | TPMT (*1/*1), NUDT15 (*1/*1) | Normal | No recommendation |

#### Gastroenterology (Antacids)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Metoclopramide | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Pantoprazole | CYP2C19 (*1/*17) | Rapid | No recommendation |
| Dexlansoprazole | CYP2C19 (*1/*17) | Rapid | No recommendation |
| Esomeprazole | CYP2C19 (*1/*17) | Rapid | No recommendation |
| Omeprazole | CYP2C19 (*1/*17) | Rapid | No recommendation |
| Rabeprazole | CYP2C19 (*1/*17) | Rapid | No recommendation |

#### Urology

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Tolterodine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Darifenacin | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Fesoterodine | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Mirabegron | CYP2D6 (*1/*4) | Intermediate | No recommendation |
| Tamsulosin | CYP2D6 (*1/*4) | Intermediate | No recommendation |

#### Rheumatology (Anti-inflammatory)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Azathioprine | TPMT (*1/*1), NUDT15 (*1/*1) | Normal | No recommendation |
| Celecoxib | CYP2C9 (*1/*1) | Normal | No recommendation |
| Flurbiprofen | CYP2C9 (*1/*1) | Normal | No recommendation |
| Piroxicam | CYP2C9 (*1/*1) | Normal | No recommendation |
| Cevimeline | CYP2D6 (*1/*4) | Intermediate | No recommendation |

#### Infectious Disease (Antifungals, Antibacterials)

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Efavirenz | CYP2B6 (*1/*1) | Normal | No recommendation |
| Dolutegravir | UGT1A1 (*1/*36) | Normal | No recommendation |
| Raltegravir | UGT1A1 (*1/*36) | Normal | No recommendation |
| Voriconazole | CYP2C19 (*1/*17) | Rapid | No recommendation |

---

## Methodology

- **Platform**: Variantyx Genomic Intelligence platform version 3.17.4.2
- **Sequencing**: Next generation sequencing (NGS) with whole genome short read sequencing
- **Confirmation**: Oxford Nanopore Technologies (ONT) PromethION 24 as needed
- **Genome Build**: GRCh38

### Statistics

- SNV sensitivity, specificity, PPV: >0.99
- Small indels (<50 bp) sensitivity: >0.95, PPV: >0.92
- CNV analytical sensitivity (>300 bp): >0.80
- CNV clinical sensitivity (any size): >0.96
- Pathogenic STR clinical sensitivity: >0.99
- PGx diploid genotypes sensitivity: >0.96, specificity/PPV: >0.98

---

## Electronically Signed By

Reena Ray Sisk PhD, FCCMG, DABMGG

---

*Source: /Users/tony/isaacstory/isaacstory2/Exams/Genetic/20240907_Variantyx_GeneticTest.pdf*
*Generated: 2026-01-28*
*Template: Genetic v1.0*